Description

Zoetis’ 8% U.S. Decline: Can Livestock Growth Offset Pet-Care Pressure?

Zoetis reported first quarter 2026 financial results reflecting a complex operating environment characterized by varying performance across its key business segments and geographies. On an organic operational basis, total company revenue was flat compared to the prior year, while adjusted net income increased by 1%. The International segment demonstrated strong growth, with a 10% increase organically, whereas the U.S. segment faced an 8% decline. Species-wise, livestock revenue grew by 12%, supported by broad-based demand and favorable market conditions, while companion animal revenues decreased by 4%, pressured by softer demand and intensifying competition. Key challenges emerged predominantly in the U.S. companion animal business, where increased price sensitivity among pet owners and slower veterinary clinic traffic combined with intensified competition, particularly in dermatology and parasiticides categories. New competitors engaged in aggressive pricing and promotions, exerting pressure on Zoetis’ market share and resulting in reduced prescription volumes and compliance.